This trial will include patients who have a heart condition called atrial fibrillation. Atrial fibrillation is an abnormal rhythm (irregular beat) in the heart. Patients with atrial fibrillation have an increased chance for a blood clot to form in the heart and move to other blood vessels in the body and cause obstruction. This obstruction may damage tissue. For example, a blood clot plugging a vessel in the brain could cause a stroke. Therefore, patients with atrial fibrillation may be given anticoagulant (blood-thinning) tablets such as warfarin or acenocoumarol.
This trial will include patients who have a heart condition called atrial fibrillation. Atrial fibrillation is an abnormal rhythm (irregular beat) in the heart. Patients with atrial fibrillation have an increased chance for a blood clot to form in the heart and move to other blood vessels in the body and cause obstruction. This obstruction may damage tissue. For example, a blood clot plugging a vessel in the brain could cause a stroke. Therefore, patients with atrial fibrillation may be given anticoagulant (blood-thinning) tablets such as warfarin or acenocoumarol.The purpose of this study is to compare the safety and effectiveness of a new injectable anticoagulant drug that is administered once weekly, SanOrg34006 (International Nonproprietary Name – idraparinux sodium), with warfarin or acenocoumarol tablets.Assignment to either SanOrg34006 (idraparinux sodium) Injection or vitamin K antagonist (warfarin or acenocoumarol) tablets will be purely by chance and will be known by both patients and their doctors.Condition:- Atrial FibrillationStudy Type: InterventionalStudy Design: Treatment, Randomized, Open Label, Safety/Efficacy StudyOfficial Title: The AMADEUS trial, A multicenter, randomized, open-label, assessor blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous idraparinux (SanOrg34006) with adjusted-dose oral vitamin-K antagonists in the prevention of thromboembolic events in patients with atrial fibrillation.EligibilityAges Eligible for Study: 18 Years and above, Genders Eligible for Study: BothCriteriaInclusion Criteria: * ECG-documented atrial fibrillation (AF) and an indication for long-term vitamin K antagonist (VKA) therapy based on the presence of at least one of the following risk factors: (a.) previous ischemic stroke, transient ischemic attack (TIA) or systemic embolism (b.) hypertension requiring drug treatment (c.) left ventricular dysfunction (left ventricular ejection fraction <45% or symptomatic congestive heart failure) (d.) age >75 years (e.) age between 65-75 years plus diabetes mellitus, or (f.) age between 65-75 years plus symptomatic coronary artery disease (previous myocardial infarction (MI) or angina pectoris) * Written informed consentExclusion Criteria: * Legal lower age limitations (country specific) * Indication for VKA other than AF, including prosthetic heart valves, venous thromboembolism, and planned cardioversion * Transient AF caused by a reversible disorder * Active bleeding or high risk of bleeding * Recent (<15 days) or anticipated invasive procedures with potential for uncontrolled bleeding, including major surgery * Participation in another pharmacotherapeutic study within the prior 30 days * Creatinine clearance <10 mL/min, severe hepatic disease, or bacterial endocarditis * Uncontrolled hypertension: systolic blood pressure > 180 mm Hg and/or diastolic blood pressure > 110 mm Hg * Pregnancy or childbearing potential without proper contraceptive measures * Any other contraindication listed in the labeling of warfarin or acenocoumarol Bondi Junction, Cairns, Camperdown, Miranda, Perth, Australia; Recruiting South Australia, Tasmania, Victoria, Australia; Recruiting Concord Repartiation General Hospital, Concord, Australia; Recruiting
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.